Table 2.
Prevalence of mildly reduced renal function and conditions affecting renal health at baseline in clinical studies of PrEP
| Population | Sample size, n | Baseline prevalence, % | References | |||
|---|---|---|---|---|---|---|
| Suboptimal eGFR levels (≥ 60–< 90 ml/min/1.73 m2) | Hyperlipidemia | Hypertension | Diabetes | |||
| MSM and transgender women in a multinational studya | 5387 | NA | 12 | 10–11 | 3 | [58] |
| MSM and transgender women in the US | 557 | 16.6 | NA | 11.3 | 1.6 | [57] |
| MSM and transgender women in a multinational studyb | 1224 | NA | NA | 2 | NA | [59] |
| Individuals at high risk of HIV in Australia | 5868 | 28.5 | NA | NA | NA | [56] |
eGFR estimated glomerular filtration rate, MSM men who have sex with men, NA not applicable, PrEP pre-exposure prophylaxis
a Includes US, Canada, UK, Italy, Spain, Netherlands, Germany, France, Austria, Ireland, and Denmark
b Includes US, Thailand, South Africa, Brazil, Ecuador, and Peru